Evidence map›Paper›PMID 41744875›Full record

ArticleCurrent oncology (Toronto, Ont.)2026

Primary Tumor Size and Tumor-Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor.

Jin Guo, Kever A Lewis, Laura Prakash, Priya Bhosale, Ajaykumar Morani, Matthew H G Katz, Ching-Wei D Tzeng, Naruhiko Ikoma, Rebecca Snyder, Michael P Kim and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jin GuoNew York Cancer & Blood Specialists, New York, NY 11776, USA.
Kever A LewisDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Laura PrakashDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-1846-2361
Priya BhosaleDepartment of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-4014-4941
Ajaykumar MoraniDepartment of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-2936-0291
Matthew H G KatzDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ching-Wei D TzengDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6035-7288
Naruhiko IkomaDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Rebecca SnyderDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael P KimDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Chandrikha ChandrasekharanDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Arvind DasariDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
James C YaoDepartment of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jeffrey E LeeDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6010-5590
Jessica E MaxwellDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Daniel M HalperinDepartment of Hematology & Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Capecitabine/temozolomide (CAPTEM) is an established regimen for patients with metastatic pancreatic neuroendocrine tumors (PanNET) that is being increasingly used for tumor volume reduction in patients with borderline anatomically resectable disease. We sought to understand the response of the primary tumor, defined as changes in the tumor-vascular interface (TVI). This is a retrospective, single-institution study of patients with locally advanced or metastatic PanNET treated with CAPTEM between 2010 and 2020. RECISTv1.1 measurements and TVI assessments of the primary tumor were performed on pre- and post-therapy images. Patients with locally advanced or metastatic PanNET at presentation (

Indexed as

capecitabinepancreas neuroendocrine tumorssurgical managementtemozolomide

Identifiers

PMID41744875
PMCPMC12939116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.